Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eva Giro

Internal Medicine Marietta, OH Medical Doctor

NPI 1104821420 CMS profile 4375

320 E 8Th St Ste 141, Marietta, OH 45750

Open in the dashboard

General payments

$9,733

580 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eva Giro of Marietta, OH is reported in the CMS Open Payments database as having received $9,733 across 580 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,406 76
2024 General $1,624 86
2023 General $1,362 79
2022 General $1,059 69
2021 General $1,676 109
2020 General $1,567 94
2019 General $1,040 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eva Giro
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Eva Giro were reported at $1,406. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Eva Giro Internal Medicine median Middle half National median
2019 $1,040 $159 $48–$570 $163
2020 $1,567 $119 $33–$402 $114
2021 $1,676 $135 $37–$521 $132
2022 $1,059 $141 $42–$496 $149
2023 $1,362 $149 $45–$519 $160
2024 $1,624 $154 $47–$537 $164
2025 $1,406 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,691 97 payments
  2. Amgen Inc. $1,253 86 payments
  3. AbbVie, Inc. $754 46 payments
  4. Amarin Pharma Inc. $749 45 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $647 42 payments
  6. Lilly USA, LLC $536 35 payments
  7. Novo Nordisk Inc $498 29 payments
  8. Pfizer Inc. $484 33 payments
  9. Exact Sciences Corporation $396 19 payments
  10. Janssen Pharmaceuticals, Inc $279 19 payments
  11. Other $2,446 129 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,696 577 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20 1 payment
  3. Education $17 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $956 52 payments
  2. Repatha $735 51 payments
  3. Otezla $687 47 payments
  4. Vascepa $673 41 payments
  5. AIRSUPRA $641 34 payments
  6. Cologuard Collection Kit $396 19 payments
  7. Ozempic $367 22 payments
  8. UBRELVY $358 20 payments
  9. EVENITY $307 20 payments
  10. INVOKANA $297 20 payments
  11. Other $8,136 496 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 160 drugs

Part D claims

12,386

Median for Internal Medicine: 777

Drug cost

$899,938

Median for Internal Medicine: $73,373

Branded share of claims

20.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 148 $153,995
Ozempic Semaglutide Brand 107 $138,221
Jardiance Empagliflozin Brand 77 $85,383
Mounjaro Tirzepatide Brand 44 $58,459
Xarelto Rivaroxaban Brand 47 $50,425
Farxiga Dapagliflozin Propanediol Brand 53 $48,313
Trulicity Dulaglutide Brand 27 $44,807
Januvia Sitagliptin Phosphate Brand 36 $35,714
Repatha Sureclick Evolocumab Brand 41 $26,343
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 32 $20,440

The 10 drugs with the highest cost, of 160 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$115,091

Medicare's payments for the services billed

Medicare patients

429

Average age 75

Services billed

1,685

281 women, 148 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 27%
Chronic kidney disease 23%
Ischemic heart disease 21%
Depression 21%
Atrial fibrillation 18%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $271
$271 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $153
$153 53 —
Otezla
  • Amgen Inc. $118
$118 — —
Repatha
  • Amgen Inc. $93
$93 41 —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $75
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

580 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record